SCHEMBL23744951

SCHEMBL23744951

O=C(O)c1cnn2c(C3CC3)ccnc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.61
HTT P42858 1/20 0.61
ALDH1A1 P00352 4/20 0.57
CREBBP Q92793 1/20 0.52
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAP2K1 Q02750 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
PLAT P00750 1/20 0.43
KDM5A P29375 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
PDE2A O00408 3/20 0.39
MAPK13 O15264 1/20 0.38
LIMK1 P53667 1/20 0.38
MARK2 Q7KZI7 1/20 0.38
PDE3B Q13370 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14014971 0.93 KDM4E (0.54) KDM4EHTTALDH1A1CREBBPMAPT
SCHEMBL23728439 0.86 KDM4E (0.59) KDM4EHTTALDH1A1CREBBPMAP2K1
SCHEMBL23728451 0.76 KDM4E (0.67) KDM4EHTTALDH1A1CREBBPPDE2A
SCHEMBL17729416 0.76 KDM4E (0.40) KDM4EHTTALDH1A1CREBBPMAPT
SCHEMBL10408157 0.76 KDM4E (0.57) KDM4EALDH1A1CREBBPMAPTSMN1; SMN2
SCHEMBL2462603 0.76 KDM4E (0.57) KDM4EALDH1A1CREBBPSMN1; SMN2MAP2K1
SCHEMBL10407220 0.74 KDM4E (0.56) KDM4EALDH1A1CREBBPMAPTSMN1; SMN2
SCHEMBL359062 0.74 KDM4E (0.57) KDM4EALDH1A1CREBBPMAP2K1CLK4
SCHEMBL18208300 0.74 KDM4E (0.56) KDM4EALDH1A1MAPTSMN1; SMN2MAP2K1
SCHEMBL18208439 0.74 KDM4E (0.64) KDM4EHTTALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885HTT 2464/4885ALDH1A1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.